Guido Junge
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications
Randomised, phase 1 evaluation of the safety, tolerability, pharmacokinetics and pharmacodynamics of iptacopan in healthy volunteers.
Journal: British journal of pharmacology
Published: August 05, 2025
Iptacopan Reduces Proteinuria and Stabilizes Kidney Function in C3 Glomerulopathy.
Journal: Kidney international reports
Published: September 26, 2024
Safety and Efficacy of Ianalumab in Patients With Sjögren's Disease: 52-Week Results From a Randomized, Placebo-Controlled, Phase 2b Dose-Ranging Study.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: February 07, 2024
First-in-human safety, tolerability, and pharmacokinetic results of DFV890, an oral low-molecular-weight NLRP3 inhibitor.
Journal: Clinical and translational science
Published: September 28, 2023
Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Journal: Kidney international reports
Published: July 14, 2023
Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy.
Journal: Kidney international
Published: December 07, 2022
Efficacy and safety of MAS825 (anti-IL-1β/IL-18) in COVID-19 patients with pneumonia and impaired respiratory function.
Journal: Clinical and experimental immunology
Published: July 18, 2022
DFV890: a new oral NLRP3 inhibitor-tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function.
Journal: Infection
Published: May 12, 2022
Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial.
Journal: Lancet (London, England)
Published: December 07, 2020
Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial.
Journal: The Lancet. Haematology
Published: October 12, 2020
Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes.
Journal: The New England journal of medicine
Published: May 17, 2018
Last Updated: 09/26/2026